CapitalBio Corporation and VWR International sign an International Supply...

CapitalBio Corporation and VWR International sign an International Supply Agreement

CapitalBio Corporation, a leading total healthcare solutions provider based in Beijing, China and VWR International, LLC, a leader in the global research laboratory supply industry, today announced that the two companies have entered into a distribution agreement. VWR will serve as CapitalBio´s major global distributor. VWR is one of the top distributors to the life science industry internationally, with a global pharmaceutical, biotechnology and educational customer-base.

Under the Agreement, VWR will distribute CapitalBio´s proprietary instrument platforms and reagents internationally, except for Greater China. This distribution agreement will expand VWR International´s product offerings particularly in the biochip sector. CapitalBio will provide all the necessary commercial and technical support for VWR´s sales and marketing efforts.

"It is very gratifying to launch our distribution agreement with such an eminent company as VWR International," commented David Sun, Senior Vice President of Corporate Business Development and Marketing of CapitalBio, "It is a milestone for us to enter the global market with VWR. At CapitalBio, we are committed to providing cutting-edge products and integrated total solution platforms. We are working together with VWR to launch our proprietary products in developed and highly competitive global markets. VWR International´s recognition of CapitalBio´s products demonstrates that CapitalBio´s products are well-suited for the global marketplace."

"CapitalBio is a recognized developer of innovative life sciences and healthcare technologies, with a first-rate R&D capability," said Brian Kerslake, VWR Vice President of Life Science, "We believe CapitalBio´s world-class products will have significant market demands in the global market. We are very glad to enter into a distribution agreement with CapitalBio; and we see a very exciting and great future in this relationship. "

"This agreement significantly enhances VWR´s network of suppliers by extending CapitalBio´s high quality and innovative microarray products and technologies to our customers," said Kerslake. "Our relationship will continue to strengthen VWR´s ability to provide our customers with superior solutions and leading-edge technology."

About VWR International, LLC

VWR International is a leader in the global research laboratory industry with worldwide sales of $3.3 billion US dollars. VWR´s business is highly diversified across products and services, geographic regions and customer segments. The company offers products from a wide range of manufacturers, to a large number of customers primarily in North America, Europe and other locations. VWR´s principal customers are major pharmaceutical, biotechnology, chemical, technology, clinical, food processing and consumer product companies, universities and research institutes, governmental agencies, environmental testing organizations, and primary and secondary schools. VWR distributes a diversified product mix, including chemicals, glassware and plasticware, equipment and instruments, furniture, protective apparel, production and safety products, and other life science and laboratory products and supplies. VWR supports its customers by providing storeroom management, product procurement, supply chain systems integration, technical services and laboratory bench top delivery. VWR maintains operations in over 20 countries and employs over 6,000 people worldwide. VWR International is headquartered in West Chester, Pennsylvania. VWR-G.

About CapitalBio

CapitalBio is a leading total solution provider for life sciences and health that develops and commercializes a broad range of products, including a range of biochip technologies for drug discovery research, genomics, proteomics, bio-safety testing and for various clinical applications. Headquartered in Beijing, China, CapitalBio has rapidly evolved from a young innovative biochip developer into a comprehensive healthcare provider with four affiliates or subsidiaries: AVIVA Biosciences, a San Diego, California based company that develops and markets on-chip patch-clamp technologies for ion-channel studies for drug discovery researches; Chipscreen Biosciences, a biotech company located in Shenzhen, China, for small molecular drug discovery and development; CapitalBio International, a fully owned subsidiary located in San Diego, California and another fully owned subsidiary CapitalBio Hong Kong. Additional information on CapitalBio can be found at www.capitalbio.com.